2012 Biotech Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2012 Biotech Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geneguru who wrote (58)	1/6/2012 2:02:01 PM
From: Arthur Radley	of 513

Guru, Needham pounding the table again today with MITI. This is twice within the last three weeks. They also issued a similar PR relating to OPTR. Nice move today, but more volume needed. Concerning the MITI office location in MD--is that just a PO drop or is there anyone working there? I've tried calling and always get an answering service. I know their major operations are run from Germany. Thanks! Needham & Company Reiterates a 'Buy' on Micromet (MITI); 2012 Preview 10:26 am ET 01/06/2012 - Street Insider Needham & Company reiterates a 'Buy' on Micromet (NASDAQ: MITI) price target of $10.00. Needham analyst says, "Micromet recently initiated a single-arm Phase 2 trial of blinatumomab designed for potential accelerated approval in adult relapsed/refractory Acute Lymphocytic Leukemia (r/r ALL). Results are expected early in 2013. A confirmatory Phase 3 randomized controlled trial is expected to begin in early 2012. We are favorably inclined based on encouraging data to date. Additional results from a dose-ranging Phase 2 trial of blinatumomab in adult r/r ALL patients at the 2011 ASH meeting demonstrated an impressive 68% CR/CRh rate, with a 75% rate at the dose and schedule selected for further development. Median survival has not been reached after a median follow-up period of 9.7 months. A 4 month median survival is typically seen in this difficult to treat population."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next